Survival analysis showed a significant increased risk of progression with high baseline IL-8 for SCLC and NSCLC patient groups combined, with an HR of 1.61 (95% CI 1.05–2.47; P=0.028) (Table 5). Here, CXCL8 is linked to non-small cell lung carcinoma.